恩曲替尼治疗ROS1融合阳性非小细胞肺癌的更新整合分析
该更新整合分析纳入三项I/II期试验(ALKA-372-001、STARTRK-1、STARTRK-2)中161例ROS1融合阳性晚期NSCLC患者,评估恩曲替尼(≥600 mg每日一次)的疗效与安全性。结果显示ORR为67.1%,中位缓解持续时间15.7个月,12个月PFS率55%,基线可测量CNS转移患者颅内ORR达79.2%,安全性谱与既往一致。
要点
- 恩曲替尼在ROS1融合阳性NSCLC中ORR达67.1%,中位DoR 15.7个月。
- 基线可测量CNS转移患者颅内ORR为79.2%,中位颅内PFS 12.0个月。
- 安全性谱与主要分析一致,未发现新的安全信号。
核心结论
- 恩曲替尼对ROS1融合阳性NSCLC患者持续显示高水平临床获益,包括合并CNS转移者。
研究设计与样本
- 更新整合分析纳入三项I期或II期临床试验(ALKA-372-001、STARTRK-1、STARTRK-2)。
- 疗效可评估人群为接受恩曲替尼≥600 mg口服每日一次的成人局部晚期或转移性ROS1融合阳性NSCLC患者,共161例,随访≥6个月。
主要发现
- 中位治疗持续时间10.7个月(IQR 6.4-17.7)。
- ORR为67.1%(n=108,95%CI 59.3-74.3),12个月DoR率63%,中位DoR 15.7个月。
- 12个月PFS率55%(中位PFS 15.7个月),12个月OS率81%(中位OS不可估计)。
- 24例基线经盲法独立中心评审有可测量CNS转移的患者中,颅内ORR为79.2%(n=19,95%CI 57.9-92.9),中位颅内PFS 12.0个月(95%CI 6.2-19.3),中位颅内DoR 12.9个月(12个月率55%)。
- 安全性谱与主要分析相似,未发现新的安全信号。
临床怎么用
- 恩曲替尼可作为ROS1融合阳性晚期NSCLC的治疗选择,尤其对合并CNS转移患者具有颅内活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine kinase inhibitor, entrectinib, in ROS1 fusion-positive NSCLC. METHODS: The efficacy-evaluable population included adults with locally advanced or metastatic ROS1 fusion-positive NSCLC with or without CNS metastases who received entrectinib ≥ 600 mg orally once per day. Co-primary end points were objective response rate (ORR) assessed by blinded independent central review and duration of response (DoR). Secondary end points included progression-free survival (PFS), overall survival (OS), intracranial ORR, intracranial DoR, intracranial PFS, and safety. RESULTS: In total, 161 patients with a follow-up of ≥ 6 months were evaluable. The median treatment duration was 10.7 months (IQR, 6.4-17.7). The ORR was 67.1% (n = 108, 95% CI, 59.3 to 74.3), and responses were durable (12-month DoR rate, 63%, median DoR 15.7 months). The 12-month PFS rate was 55% (median PFS 15.7 months), and the 12-month OS rate was 81% (median OS not estimable). In 24 patients with measurable baseline CNS metastases by blinded independent central review, the intracranial ORR was 79.2% (n = 19; 95% CI, 57.9 to 92.9), the median intracranial PFS was 12.0 months (95% CI, 6.2 to 19.3), and the median intracranial DoR was 12.9 months (12-month rate, 55%). The safety profile in this updated analysis was similar to that reported in the primary analysis, and no new safety signals were found. CONCLUSION: Entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including patients with CNS metastases.
引用
- Dziadziuszko R, Krebs MG, De Braud F, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021. PMID: 33646820. doi:10.1200/JCO.20.03025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。